Stay up to date with the latest news and events from the NIHR Manchester Biomedical Research Centre.
The Manchester Molecular Pathology Innovation Centre (MMPathIC) is hosting an Interdisciplinary Workshop on 14th February 2018.
Continue reading full article: Manchester Molecular Pathology Innovation Centre – Interdisciplinary Workshop: Engaging Engineers and Physical Scientists
The Future In Your Hands - a photography exhibition celebrating musculoskeletal conditions
Continue reading full article: The Future In Your Hands – a photography exhibition celebrating musculoskeletal conditions
A team at The University of Manchester have found that in a minority of patients they studied, the standard treatment for asthma - oral steroids - was associated with increased levels of the treatable mould Aspergillus in the lung.
Continue reading full article: Mould discovery in lungs paves way for helping hard to treat asthma
The Manchester BRC is advertising nine specialised PhD studentships across a number of clinical and non-clinical areas. The deadline for applications is 2 February.
Continue reading full article: NIHR Manchester BRC PhD studentships – deadline 2 February
Professor Caroline Dive and Professor Chris Griffiths have been honoured by the Queen in the 2018 New Year’s Honours list.
Continue reading full article: Manchester BRC researchers named in New Year’s Honours List
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women – according to new research.
Continue reading full article: Screening could catch a quarter of hip fractures before they happen
This event in partnership with Manchester Precision Medicine Institute and Health Innovation Manchester will provide attendees with an understanding of precision medicine approaches and an overview of some of the existing research in this area across Manchester and within industry.
Continue reading full article: Event – How Precision Medicine will transform healthcare – 2 March 2018
Researchers set out to determine whether three of the recommended biologic therapies (etanercept, adalimumab or ustekinumab) for psoriasis elevate the risk of serious infection above that for non-biologic, conventional tablet treatments.
Continue reading full article: Researchers find no increased risk of serious infection when comparing biologic and non-biologic psoriasis treatments